Achaogen Announces Key Appointments to Leadership Team and Board

South San Francisco, CA, February 20, 2014 – Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the appointments of Derek Bertocci as Chief Financial Officer and John Smither as a member of the Board of Directors, serving as Audit Committee Chair and member of the Compensation Committee. Mr. Bertocci brings significant financial and accounting experience to Achaogen having served as Chief Financial Officer to several publicly-traded life science and medical products companies. Mr. Smither currently serves as the Chief Financial Officer of KYTHERA Biopharmaceuticals, a publicly-traded biotech company focused on the aesthetic market, and has an extensive financial background working with life science companies.

"On behalf of the management and Board of Achaogen, I am delighted to welcome Derek and John to our team," said Kenneth Hillan, Chief Executive Officer of Achaogen. "Both are accomplished executives with substantial experience that will be valuable to Achaogen as we continue to advance plazomicin and our other development programs."

Prior to joining Achaogen, Mr. Bertocci was the Chief Financial Officer of Accuray Incorporated, where he managed all finance and accounting efforts and helped guide Accuray's acquisition of TomoTherapy. In addition, he was responsible for outlining and implementing Accuray's worldwide restructuring efforts designed to improve after-tax profitability. Previously, Mr. Bertocci served as Chief Financial Officer of BioForm Medical, where he helped lead the company's successful initial public offering in 2007. Earlier in his career, he served as Chief Financial Officer of two other publicly-traded companies, VISX Incorporated and Laserscope. He holds a BA from Stanford University, and an MBA from the University of Southern California. Mr. Bertocci is also a Certified Public Accountant (inactive).

Mr. Smither brings to Achaogen's Board nearly 15 years of experience across financial roles at publicly-traded, commercial and late-stage clinical companies. He has served as KYTHERA's Chief Financial Officer since November 2007, where he has spearheaded multiple capital raising efforts, including the company's successful IPO in late 2012, its venture debt facility and a successful follow-on public offering in 2013. From 1998 to 2007, Mr. Smither held various positions at Amgen, including Executive Director of Corporate Accounting, Vice President of Finance and Administration of Amgen's European Division, and Head of Internal Audit. Before Amgen, Mr. Smither served as Audit Partner at Ernst & Young LLP, a public accounting firm, and as the Chief Financial Officer of several early stage companies. He received a BS in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.

About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Through the Special Protocol Assessment procedure, the U.S. Food and Drug Administration has agreed that the design and planned analyses of our single pivotal Phase 3 trial adequately address objectives in support of a New Drug Application. Our plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from our gram-negative antibiotic discovery engine, and we have other programs in early and late preclinical stages focused on other MDR gram-negative infections.

Contact
Candice Knoll
Blueprint Life Science Group
415.375.3340 Ext. 105
cknoll@bplifescience.com

Achaogen Files Registration Statement with SEC for Proposed Initial Public Offering

South San Francisco, CA, January 28, 2014 – Achaogen, a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined.

Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. William Blair & Company, L.L.C. and Needham & Company, LLC are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
 

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, Telephone: (800) 221-1037, Email: newyork.prospectus@credit-suisse.com; or Cowen and Company, LLC c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by calling (631) 274-2806, or by fax (631) 254-7140.
 

About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Through the Special Protocol Assessment procedure, the U.S. Food and Drug Administration has agreed that the design and planned analyses of our single pivotal Phase 3 trial adequately address objectives in support of a New Drug Application. Our plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from our gram-negative antibiotic discovery engine, and we have other programs in early and late preclinical stages focused on other MDR gram-negative infections.

Contact:
Candice Knoll
Blueprint Life Science Group
415.375.3340 Ext. 105
cknoll@bplifescience.com

Achaogen Announces Agreement with FDA on a Special Protocol Assessment for a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE)

South San Francisco, CA, September 23, 2013 – Achaogen, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 clinical trial of plazomicin in patients with serious multi-drug resistant (MDR) gram-negative bacterial infections. SPA agreement from the FDA indicates that the design and planned analyses of the clinical trial address objectives necessary to support a new drug application (NDA). This Phase 3 trial is designed as a superiority study to evaluate the efficacy and safety of plazomicin compared with colistin in patients with bloodstream infections and nosocomial pneumonia caused by CRE.

“Reaching agreement with the FDA on the plazomicin Phase 3 study design is a significant milestone for Achaogen as well as a meaningful step forward in antibiotic drug development for new regulatory pathways that address serious unmet medical needs,” said Kenneth Hillan, M.B. Ch.B, Chief Executive Officer and Chief Medical Officer for Achaogen. “FDA agreement on this protocol provides a clear path for a streamlined development plan for plazomicin. The trial is expected to start in fourth quarter, 2013.”

CRE are a global and growing public health concern. These bacteria are resistant to nearly all available antibiotics, including carbapenems, one of the last lines of defense against resistant infections. Mortality rates approach 50% in CRE patients with bloodstream infections, and the U.S. Centers for Disease Control and Prevention has categorized CRE as an “urgent” public health threat requiring immediate and aggressive action.

Plazomicin is a next-generation aminoglycoside antibiotic that Achaogen engineered to overcome key aminoglycoside resistance mechanisms. It has potent bactericidal activity against important gram-negative pathogens, including CRE. Plazomicin is also being developed for the treatment of infections caused by certain biothreat agents, including Yersinia pestis and Francisella tularensis (which cause plague and tularemia, respectively). The development of plazomicin is supported by the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.

About Achaogen
Achaogen is a biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for serious infections caused by MDR gram-negative bacteria. In addition to its lead asset plazomicin, the company has active research and early development programs focused on novel mechanisms targeting gram-negative bacteria. Achaogen has established and advanced its specialized research and development capabilities using a blend of funding from private investors and partnerships with governmental entities, including BARDA, the National Institute of Allergy and Infectious Diseases, and the U.S. Department of Defense. For more information, please visit the company’s website at www.achaogen.com.

Media Contact:
Jennifer Cheung, Achaogen
1-650-452-6159
jcheung@achaogen.com

Investor Contact:
Dennis Hom, Achaogen
1-650-741-1237
dhom@achaogen.com

Achaogen Awarded $60M Contract Option by BARDA for the Clinical Development of Plazomicin

- Contract to fund Phase 3 superiority study of plazomicin in patients with carbapenem-resistant Enterobacteriaceae (CRE) infections -

South San Francisco, CA, April 24, 2013 – Achaogen, Inc. today announced the award of a $60M contract option from the Biomedical Advanced Research and Development Authority (BARDA). The option supports the conduct of a global Phase 3 superiority study that will evaluate the efficacy and safety of plazomicin in treating patients with serious gram-negative bacterial infections due to CRE.  This pathogen-specific clinical study represents a new development approach to address unmet medical needs for multi-drug resistant bacterial infections. The study is expected to start in fourth quarter of 2013.

“We are excited and honored to continue the development of plazomicin in partnership with BARDA,” said Kenneth J. Hillan, M.B. Ch.B., Chief Executive Officer and Chief Medical Officer of Achaogen. “The growing prevalence of CRE infections poses a substantial public health threat, given the high mortality rates associated with CRE infections. Plazomicin’s strong potential to address this public health issue and to contribute to the global effort to guard against bacterial biothreats makes it a critically important agent in the antibacterial pipeline.”

Plazomicin is a next-generation aminoglycoside antibiotic that Achaogen engineered to overcome key aminoglycoside resistance mechanisms. It has potent bactericidal activity against important gram-negative pathogens, including strains resistant to carbapenem antibiotics – one of the last lines of defense against resistant infections. Plazomicin is also being developed for the treatment of infections caused by certain biothreat agents, including Yersinia pestis, which causes plague, and Francisella tularensis, which causes tularemia.

The contract option was issued under BARDA’s Broad Spectrum Antimicrobials (BSA) program, extending Achaogen’s original contract awarded in September of 2010 with initial committed funding of $27M. In 2012, BARDA exercised an additional $16M contract option. The new option announced today brings the total value of the contract to $103M.

About Achaogen
Achaogen is a biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for serious infections caused by multi-drug resistant (MDR) gram-negative bacteria. In addition to plazomicin, the company's pipeline includes ACHN-975, a first-in-class LpxC enzyme inhibitor which is currently in Phase 1 clinical development. Achaogen has established and maintained its specialized research and development capabilities using a blend of funding from private investors and partnerships with governmental entities, including BARDA, the National Institute of Allergy and Infectious Diseases, and the U.S. Department of Defense. For more information, please visit the company’s website at www.achaogen.com.

Media Contact:
Jennifer Cheung, Achaogen
1-650-452-6159
jcheung@achaogen.com

Investor Contact:
Dennis Hom, Achaogen
1-650-741-1237
dhom@achaogen.com

Achaogen Announces All Objectives Met in Phase 2 Plazomicin Complicated Urinary Tract Infections Study and Start of First-in-Human Study with ACHN-975

- Key milestones achieved with two internally-discovered clinical candidates being developed to treat multi-drug resistant Gram-negative infections - 

South San Francisco, CA, May 15, 2012 – Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults. Achaogen is developing plazomicin, a next-generation aminoglycoside that overcomes common bacterial resistance mechanisms, as an intravenous treatment for serious Gram-negative bacterial infections, including those caused by multi-drug resistant (MDR) Escherichia coli and Klebsiella pneumoniae. This Phase 2 study of plazomicin was partially funded by the Wellcome Trust, a global charitable foundation. In addition, the Biomedical Advanced Research and Development Authority (BARDA) previously awarded Achaogen up to $64.5 million in funding to support the development of plazomicin as a potential medical countermeasure against the biothreat pathogens, Yersinia pestis and Francisella tularensis.

The Phase 2 study met its objectives of assessing safety and efficacy of plazomicin in comparison to levofloxacin. Plazomicin was well-tolerated and demonstrated favorable microbiological and clinical outcomes at the Test-of-Cure Visit, 5 to 9 days after the end of therapy, which were the primary and secondary outcome measures in this study, respectively. Achaogen intends to present data from the study at an upcoming medical conference.

"We are pleased that the data from this Phase 2 trial support plazomicin's potential utility as an important new treatment option for patients with certain serious Gram-negative bacterial infections," said Kenneth J. Hillan, M.B. Ch.B., Chief Executive Officer and Chief Medical Officer of Achaogen. "We plan to consult with the FDA regarding the design of future studies with plazomicin, which we intend to initiate in the first half of 2013. Our goal is to conduct innovative studies that would evaluate plazomicin's effectiveness in treating seriously ill patients for whom currently available therapies are ineffective."

Achaogen, Inc. also announced today that it has begun dosing in the first-in-human clinical trial of ACHN-975, a first-in-class LpxC inhibitor that is being developed for the treatment of serious infections caused by MDR Gram-negative bacteria, including pan-drug resistant Pseudomonas aeruginosa. The investigational new drug application for ACHN-975 was filed with the U.S. Food and Drug Administration (FDA) in the first quarter of 2012. The Phase 1 randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of ACHN-975 in healthy volunteers. The study is funded under a contract award to Achaogen by the Defense Medical Research and Development Program. A second Phase 1 study of multiple ascending doses of ACHN-975 administered for up to 14 days is planned to follow the single dose study.

"Our mission at Achaogen is to discover and develop antibiotics to treat patients with life-threatening bacterial infections," Hillan added. "The advancement of ACHN-975 into human clinical studies represents an important scientific milestone in our field and an opportunity to work with clinicians and regulators to establish an appropriate development path for an antibiotic with exceptional potency against Pseudomonas aeruginosa, a pathogen that kills tens of thousands of people every year."

About Achaogen
Achaogen is a biopharmaceutical company dedicated to discovering and developing treatments for serious infections caused by multi-drug resistant (MDR) Gram-negative bacteria. The company's pipeline of antibacterial drug candidates includes plazomicin (ACHN-490), a next-generation aminoglycoside in Phase 2 clinical development, ACHN-975, a first-in-class LpxC-inhibitor in Phase 1 clinical development, and one earlier-stage molecule that also targets MDR Gram-negative bacteria. Achaogen has established and maintained its specialized research and development using a blend of funding from private investments and partnerships with governmental entities, including BARDA, the National Institute of Allergy and Infectious Diseases (NIAID), and the U.S. Department of Defense. For more information, please visit the company’s website at www.achaogen.com

Media Contact:
Chris Castro, Castro Communications LLC
(310) 753-9913
chris@castrocommunicationsllc.com

Investor Contact:
Shari Annes, Annes Associates
(650) 888-0902
sannes@annesassociates.com

Achaogen Appoints Chief Medical Officer Kenneth Hillan to Chief Executive Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Achaogen, Inc., a biopharmaceutical company discovering and developing treatments for life-threatening, multi-drug resistant (MDR) Gram-negative bacterial infections, announced today that the company's board of directors has appointed Kenneth J. Hillan, M.B. Ch.B., the company’s chief medical officer, to succeed J. Kevin Judice, Ph.D., as chief executive officer and member of the board of directors effective October 3, 2011. Dr. Hillan will continue in his role as chief medical officer of the company. 

"We are deeply grateful to Kevin for his leadership of Achaogen since the company was founded in 2004,” said Bryan E. Roberts, Ph.D., general partner, Venrock Associates, and chairman of the Achaogen Board of Directors. “With three promising drug development programs and an exceptional team, Achaogen is well positioned to continue its mission."

Dr. Judice commented, "I am extremely proud of the team and the pipeline we have built at Achaogen, and believe the organization is well positioned for the future. Kenneth’s established track record of building successful leadership teams and in drug development make him the ideal candidate to ensure that Achaogen capitalizes on its opportunities to bring important new antibiotics to patients."

"I would like to thank Kevin for his leadership of Achaogen thus far, and for bringing the organization through a critical period of development,” added Dr. Hillan. “We are on track to complete a Phase 2 study for plazomicin (ACHN-490) for the treatment of complicated urinary tract infection and acute pyelonephritis in 2012, and have two additional compounds for which we anticipate submitting Investigational New Drug (IND) applications to the Food and Drug Administration in the next three to six months. With support from experienced healthcare investors and our partnerships with NIH and the U.S. Departments of Health and Defense, we believe we are well positioned to advance our pipeline in an innovative way that best addresses the acute need for new drugs to treat serious infections caused by MDR Gram-negative bacteria."

Dr. Hillan joined Achaogen as chief medical officer in April 2011, bringing deep experience in both medicine and global drug development. He spent the previous 16 years with Genentech (now part of the Roche group), where he most recently served as senior vice president and head of product development, Asia Pacific, with responsibility for Roche’s overall drug development strategy in the region. Prior to that, he was senior vice president, clinical development, inflammation after holding a variety of positions at Genentech including vice president, research operations and pathology; vice president, development sciences; and vice president, immunology, tissue growth and repair. Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents. He holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, and is a Fellow of the UK’s Royal College of Surgeons (FRCS), and of the Royal College of Pathologists (FRCPath).

About Achaogen, Inc.
Achaogen is a clinical-stage biopharmaceutical company dedicated to discovering and developing treatments for serious infections that address the significant, growing, unmet medical need caused by multi-drug resistant Gram-negative bacteria. The company’s pipeline includes plazomicin (ACHN-490), an aminoglycoside currently being evaluated in a Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis, and late-stage preclinical programs with differentiated activity against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Resistance to available antibacterial therapies continues to rise, and Achaogen has established specialized capabilities to pursue the discovery and development of new antibiotics, funding its growth with a blend of private investments and non-dilutive funding from partnerships with BARDA, NIAID, the United States Department of Defense, and others. For more information, please visit the company’s website at www.achaogen.com.

Media Contact:
Sheryl Seapy, Pure Communications Inc.
(949) 608-0841 

Achaogen Appoints Kenneth J. Hillan, M.B. Ch.B., to Chief Medical Officer

- Dr. Hillan Brings Significant Experience in Pipeline Strategy and Global Drug Development -

SOUTH SAN FRANCISCO, Calif., March 22, 2011 – Achaogen, Inc., a biopharmaceutical company discovering and developing antibiotics for the treatment of life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the hiring of Kenneth J. Hillan, M.B. Ch.B., as chief medical officer. Dr. Hillan will fill a key role on the company’s senior leadership team with responsibility for all clinical development and regulatory activities as well as pipeline strategy.

“We are thrilled to welcome Kenneth as Achaogen’s chief medical officer,” said J. Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. “His capabilities as a strategic thinker and his broad experience in global drug development across multiple therapeutic areas make him the ideal leader to join our team. Our mission to discover and develop new treatments for life-threatening, MDR bacterial infections is a critical one, and Kenneth’s arrival at Achaogen is a vital part of our pursuit of creative solutions to the many challenges inherent in the development of new antibiotics.”

Dr. Hillan joins Achaogen after sixteen years with Genentech (now Roche), where he most recently served as senior vice president and head of product development, Asia Pacific, with responsibility for Roche’s overall drug development strategy in the region. Prior to that, he was senior vice president, clinical development, inflammation after holding a variety of positions at Genentech including vice president, research operations and pathology; vice president, development sciences; and vice president, immunology, tissue growth and repair (ITGR). Dr. Hillan has also authored dozens of scientific publications and is a named inventor on almost 50 issued patents. He holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, and is a Fellow of the Royal College of Surgeons (FRCS), and of the Royal College of Pathologists (FRCPath).

“I am very excited to join Achaogen,” Dr. Hillan commented. “The company’s rigorous science and focus on multi-drug-resistant pathogens – an area that has suffered from a lack of scientific investment and innovation in recent years – presents a unique opportunity to identify, develop and commercialize new medicines for a patient population with a significant and growing unmet medical need. I look forward to working with the rest of the team as we continue to build Achaogen into a fully integrated pharmaceutical company.”

About Achaogen
Achaogen is a clinical-stage biopharmaceutical company focused on the discovery and development of antibiotics for the treatment of serious infections caused by multi-drug resistant, Gram-negative bacteria. The company’s pipeline includes ACHN-490, an aminoglycoside currently being evaluated in a Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis, and late-stage preclinical programs with demonstrated in vivo efficacy against Gram-negative pathogens of concern including P. aeruginosa and A. baumannii. Resistance to available antibacterial therapies continues to rise at an alarming rate and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today intended to combat tomorrow’s resistant pathogens. Achaogen has established specialized capabilities to pursue the discovery and development of new antibiotics, and has funded its growth with a blend of private investments and non-dilutive funding from partnerships with the NIH, the United States Department of Defense, and others. For more information, please visit the company’s website at www.achaogen.com.

Contact:
Sheryl Seapy
Pure Communications, Inc.
(949) 608-0841
sheryl@purecommunicationsinc.com

Achaogen to Present New Data on ACHN-490 at the 50th Annual ICAAC Meeting

- Presentations Highlight Data from Phase 1 Study with ACHN-490 and In Vitro Activity of ACHN-490 Against Resistant Bacterial Pathogens and in Combination with Existing Antibiotics -

SOUTH SAN FRANCISCO, Calif., September 9, 2010 – Achaogen, a biopharmaceutical company and developing antibiotics to treat life-threatening, multi-drug resistant (MDR), today announced key upcoming data presentations involving its lead antibiotic candidate ACHN-490. The data are being presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston from September 12th through September 15th, 2010.

  •  Monday, September 13th from 11:15 am to 1:15 pm: Poster A1-658/7, entitled “Pharmacokinetics (PK) and Safety of ACHN-490 Injection Administered Intravenously for Five Days in Healthy Human Subjects.”
  •  Tuesday, September 14th from 11:15 am to 1:15 pm: Poster E-1563/226, entitled “Activity of ACHN-490 Against Isolates of Methicillin-resistant Staphylococcus aureus (MRSA) from Patients in U.S. Hospitals.”
  •  Wednesday, September 15th from 9:00 am to 11:00 am: Poster E-2059/74, entitled “Activity of ACHN-490, a Neoglycoside, against E. coli (EC) and K. pneumoniae (KP) isolates from New York City (NYC).”
  •  Wednesday, September 15th from 9:00 am to 11:00 am: Poster E-2048/63, entitled “Activity of ACHN- 490 +/- Cefepime, Doripenem, Imipenem, or Piperacillin/Tazoactam Against 10 P. aeruginosa by Synergy Time-Kill.”

In addition to the poster presentations, on Monday, September 15th from 9:00 am to 9:30 am, George H. Miller, Ph.D., research fellow at Achaogen, will be presenting “Aminoglycosides: Past, Present and Future” as part of the Symposium: “Antibiotic Drug Discovery: How Far Have We Come in 50 Years?” Following the meeting, full versions of the posters will be available on the Achaogen website at www.achaogen.com.

About ACHN-490
Achaogen’s most advanced compound, ACHN-490, has been chemically engineered to retain activity against bacteria resistant to carbapenems, cephalosporins, fluoroquinolones, tetracyclines, and legacy aminoglycosides. The compound has demonstrated bactericidal activity in vitro and efficacy in preclinical studies against systemic infections caused by MDR Gram-negative bacteria (e.g., K. pneumoniae, E. coli, and P. aeruginosa) and MRSA. ACHN-490 Injection is currently being investigated in a randomized, doubleblind, comparator-controlled Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI), the most commonly treated hospital infections in the U.S., and acute pyelonephritis.

About Achaogen
Achaogen is a biopharmaceutical company focused on the discovery and development of antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today intended to combat tomorrow’s resistant pathogens. Achaogen has established specialized capabilities that have enabled the company to pursue multiple discovery and development programs, and has funded its growth with an innovative blend of private investments and non-dilutive funding from partnerships with the NIH, BARDA, the United States Department of Defense, and others. For more information, please visit the company’s website at www.achaogen.com. 

Contacts:
Ashlea Kosikowski, Pure Communications
(910) 547-7093

Achaogen Awarded Contract Worth up to $64 Million by BARDA for the Development of ACHN-490

- Achaogen has Raised More Than $150 Million in Non-Dilutive Funding -

SOUTH SAN FRANCISCO, Calif., August 30, 2010 – Achaogen, a biopharmaceutical company discovering and developing innovative antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the award of a contract with The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. The contract covers development, manufacturing, and regulatory activities that would position Achaogen’s lead antibiotic candidate ACHN-490 for the treatment of certain biothreat agents, including Yersinia pestis, which causes bubonic plague, and Francisella tularensis, which causes tularemia. The same activities will also provide significant value to the Company’s overall development program for ACHN-490, which includes other life-threatening indications such as complicated urinary tract infections and hospital-acquired pneumonia.

The contract includes a two-year base period with committed funding of $27 million and subsequent option periods that, if completed, would bring the total value of the award to $64.5 million.

“We are pleased to be the first awardee from BARDA’s broad-spectrum antimicrobial initiative” said J. Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. “BARDA serves a critical leadership role in the global effort to combat bacterial biothreats and multi-drug resistance at a time when commercial investment is insufficient to meet the challenges we are facing. We look forward to working with BARDA and contributing to global efforts to combat bacterial biothreats and bacterial resistance as we continue the development of ACHN-490.”

With this award, Achaogen has secured significant, non-dilutive funding for all of its ongoing drug discovery and development programs. In aggregate, upon successful completion of its existing government contracts, Achaogen will have received more than $150 million in nondilutive funding.

About ACHN-490
ACHN-490, Achaogen’s most advanced compound, combines excellent solubility, stability, and physicochemical properties with an in vitro spectrum of activity that includes current and emerging multi-drug resistant (MDR) pathogens. ACHN-490 has been chemically engineered to retain activity against bacteria resistant to carbapenems, cephalosporins, fluoroquinolones, tetracyclines, and legacy aminoglycosides. It has demonstrated potent bactericidal activity in vitro and efficacy in preclinical animal models against infections caused by MDR Gram-negative bacteria (e.g., K. pneumoniae, E. coli, and P. aeruginosa) and MRSA. ACHN-490 Injection is being investigated in a randomized, double-blind, comparator-controlled Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI), the most commonly treated hospital infections in the U.S., and acute pyelonephritis. Subsequent clinical studies are being considered to evaluate ACHN-490 Injection in additional indications, including hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated intra-abdominal infections (cIAI) and blood stream infections (BSI).

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today that will combat tomorrow’s resistant pathogens. Through the use of non-dilutive funding from partnerships with the NIH, the Department of Defense, and BARDA to augment funding from venture investors, Achaogen has established specialized capabilities that have enabled the company to pursue multiple discovery and development programs.

Contacts:
Ashlea Kosikowski, Pure Communications
(910) 547-7093

Achaogen Completes $56 Million Series C Financing

- Proceeds Will Continue to Advance Clinical Development of Novel Antibiotics to Combat Multi-Drug Resistant Gram-Negative Bacteria and MRSA -

SAN FRANCISCO, Calif., April 7 , 2010 – Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the completion of a $56 million Series C round of financing. The round was led by new investor Frazier Healthcare Ventures, and also included new investor Alta Partners. Current investors 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and the Wellcome Trust also participated in the round. In conjunction with this financing, Robert More, general partner, Frazier Healthcare Ventures, will join the Achaogen board of directors.

“We appreciate the strong support of our existing investors and are pleased to welcome Frazier Healthcare Ventures and Alta Partners to the Achaogen team,” stated Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. “Our mission is to discover and develop life-saving antibiotics. This financing together with non-dilutive capital that we have secured through partnerships with various government agencies will enable us to advance multiple clinical programs, including conducting a Phase 2 study in complicated urinary tract infections of ACHN-490, our lead candidate for multi-drug resistant bacterial infections.”

“Frazier Healthcare is excited to work with Alta Partners and Achaogen’s existing investors to support the company’s growth,” said Robert More, general partner, Frazier Healthcare. “Achaogen combines excellent science with a compelling business model, blending venture capital and non-dilutive financing to advance multiple programs that have potential to address the increasing dire need for new agents to treat multi-drug resistant bacteria worldwide.”

Mr. More is a member of Frazier Healthcare’s biopharma and medical device investment teams. Prior to Frazier Healthcare, Mr. More was a partner with Domain Associates. He has also served as the chief operating officer of Small Molecule Therapeutics. Mr. More has served on the boards of ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), Onux Medical (acquired by C.R. Bard), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan) and IntraLase (acquired by Advanced Medical Optics, Inc.).

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today that will combat tomorrow’s resistant pathogens. Through the use of non-dilutive funding from partnerships with the NIH and Department of Defense to augment funding from venture investors, Achaogen has established specialized capabilities that have enabled the company to pursue multiple discovery and development programs. The company’s most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

For more information, please visit the company’s website at www.achaogen.com.

Contact:
Ashlea Kosikowski, Pure Communications
(910) 547-7093

Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting

- Achaogen’s Neoglycoside Shown to be Well-Tolerated in Phase 1, Dose-Ranging Clinical Trial -

- Additional Preclinical Data Validates ACHN-490’s Consistent Activity Against Gram-Negative and Aminoglycoside-Resistant Bacteria -

SAN FRANCISCO, CA, September 14, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA. ACHN-490 has shown preclinical activity against multi-drug resistant (MDR) Gram-negative and Gram-positive pathogens, and is the most advanced drug in Achaogen’s next-generation aminoglycosides, or neoglycosides.

“We are very pleased with the safety data observed in this Phase 1 clinical trial of ACHN-490,” said Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. “The clinical safety data combined with the powerful preclinical efficacy data reinforces ACHN-490’s potential as a novel treatment for multi-drug resistant bacterial infections. We will continue to explore the clinical utility of ACHN-490 in Phase 2 trials, expected to commence in early 2010.”

The Phase 1 trial explored the safety, tolerability and pharmacokinetics (PK) of ACHN-490 in escalating single dose (SD) and once-daily multiple doses (MD) at five different dose levels in a randomized, double blind, placebo-controlled design. Thirty-two subjects were evaluated in four arms of eight subjects per arm (6 active, 2 placebo). There was no evidence of any treatment-related effects on renal, cochlear or vestibular function. Results support the further study of ACHN-490 in high-dose, once-daily, short course therapy in patients with serious infections.

Achaogen also presented additional preclinical data of ACHN-490 in eight posters at ICAAC. Key findings included:

  • ACHN-490 is metabolically stable and its PK profile supports use of high doses in short infusions, administered once-daily to achieve high Cmax and AUC, which are important for safety and efficacy.
  • ACHN-490 demonstrated a potent, rapid, bactericidal effect for strains harboring known resistance mechanisms to widely-used aminoglycosides.
  • ACHN-490 demonstrated consistent activity against leading Gram-negative pathogens, including those with increasingly prevalent resistance mechanisms to other classes of antimicrobial agents.
  • ACHN-490 showed promise as a novel agent against Enterobacteriaceae, including multi-drug resistant KPC+ strains.
  • ACHN-490 is active against pathogens that are the leading causes of complicated urinary tract infections (cUTI), even in the presence of mechanisms causing resistance to current front-line antimicrobial agents.

The ACHN-490 Phase 1 and preclinical data abstracts and posters presented at ICAAC are available online through Achaogen’s website at www.achaogen.com.

“The exciting thing about the preclinical and clinical data on ACHN-490 presented at ICAAC is the translatability of the preclinical efficacy data into humans, combined with the positive safety profile observed in healthy volunteers,” stated Joseph S. Solomkin, M.D., professor of surgery at the University of Cincinnati. “With antibiotic drug development, the results we see in animal models tend to be more predictive of human experience because the microbials or bugs are the same – only the host is different. With that in mind, these data are very promising for ACHN-490 as an emerging weapon in the fight against multi-drug resistant bacteria.”

About ACHN-490
Achaogen’s novel aminoglycoside agents—neoglycosides—overcome known aminoglycoside resistance mechanisms as well as resistance mechanisms that thwart other well-known classes of antibiotics. Leveraging modern chemistry and biology, as well as the extensive scientific and clinical knowledge gained from decades of aminoglycoside usage, Achaogen is poised to enhance the prominence and utility of this important class of antibacterials against 21st-century pathogens.

Achaogen’s lead neoglycoside, ACHN-490, has displayed efficacy in research and nonclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. Achaogen recently completed a Phase 1 randomized, double blind, placebo-controlled trial assessing the safety, tolerability and pharmacokinetics in escalating single (SD) and once-daily multiple (MD) doses up to five doses of ACHN-490. Achaogen plans to initiate a Phase 2 clinical trial of ACHN-490 in patients with complicated urinary tract infections (cUTI) in early 2010.

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science, developing drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis.

South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

Contacts:
Dan Budwick, Pure Communications
(973) 271-6085

Ashlea Kosikowski, Pure Communications
(910) 547-7093

Achaogen Appoints John C. Doyle to the Newly Created Position of Chief Operating Officer

San Francisco, CA, August 25, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, announced today the appointment of John C. Doyle to the newly created position of chief operating officer. Mr. Doyle brings years of experience in leadership roles managing business and financial operations, strategic and operational planning, equity financing, strategic alliances and R&D program management with biotechnology companies including Genentech, Renovis and Tularik.

“As we continue to expand and develop our pipeline and prepare to enter Phase 2 development with our lead product candidate ACHN-490, we are planning for the future growth of Achaogen,” said Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. “John’s experience in both large and emerging biotech companies, as well as his diverse background in public and private financings, corporate development and operations, will be important to Achaogen as we continue to execute on our business strategy.”

Mr. Doyle joins Achaogen from Genentech, a leading biotech company acquired by Roche in March 2009, where he served as vice president of finance and corporate planning. Previously, he served as chief financial officer and senior vice president of corporate development at Renovis (acquired by Evotec AG), a publicly-held biotech company focused on neurological diseases and disorders. Mr. Doyle has also held positions at Tularik (acquired by Amgen) and PricewaterhouseCoopers. Mr. Doyle received an M.B.A. from the Haas School of Business at the University of California, Berkeley, and a B.S. from Cal Poly, San Luis Obispo.

“There is a clear and growing need for new antibiotics as multi-drug resistant bacterial infections become more prevalent worldwide,” commented Mr. Doyle. “The Achaogen team is deeply committed to addressing this serious and growing threat to public health and I am excited to join the effort.”

About ACHN-490
Achaogen’s novel aminoglycoside agents—neoglycosides—overcome known aminoglycoside resistance mechanisms as well as resistance mechanisms that thwart other well-known classes of antibiotics. Leveraging modern chemistry and biology, as well as the extensive scientific and clinical knowledge gained from decades of aminoglycoside usage, Achaogen is poised to enhance the prominence and utility of this important class of antibacterials against 21st-century pathogens.

Achaogen’s lead neoglycoside, ACHN-490, has displayed efficacy in research and nonclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. The company initiated a Phase 1 clinical study in early 2009 and data from this study are expected in the second half of 2009.

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science, developing drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis.

South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

Contacts:
Ashlea Kosikowski, Pure Communications
(910) 547-7093

FierceBiotech Names Achaogen as One of the “Fierce 15" Biotech Companies of 2009

- Achaogen is on Leading Edge of Biotech -

San Francisco, CA, June 30, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today that it has been selected as one of the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2009. The editors of FierceBiotech evaluated hundreds of privately-held firms based on vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position.

An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day’s top stories, with a special focus on drug discovery and clinical trials.

“New insights have helped Achaogen create a new and differentiated antibiotic – and that’s important in a field that is dominated by therapies fated to become obsolescent. An innovative blend of venture capital and non-dilutive financing sources has helped bankroll this five-year-old biotech, which is firmly focused on improved efficacy with fewer side effects. Achaogen has good science and a sound business model, which is rarely paired in any industry,” said John Carroll, Editor of FierceBiotech.

"FierceBiotech is highly valued for its advanced understanding of biotechnology companies and the industry as a whole," said Kevin Judice, Ph.D., Chief Executive Officer and Chief Scientific Officer of Achaogen. "Being selected as a member of the ‘Fierce 15’ is an honor that recognizes Achaogen’s potential to make a significant impact in the biotech and antibacterial market.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. The complete list of ‘Fierce 15’ companies is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science, developing drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis.

South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

About FierceMarkets
FierceMarkets is a digital business media serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets publications reach more than 450,000 executives in over 100 countries every business day. Current publications include The Business VoIP Report (http://www.businessvoipreport.com), FierceBioResearcher (http://www.fiercebioresearcher.com), FierceBiotech (http://www.fiercebiotech.com), FierceBroadbandWireless (http://www.fiercebroadbandwireless.com), FierceCIO (http://www.fiercecio.com), Fierce CIO: Tech Watch (http://www.fiercecio.com/techwatch), FierceDeveloper (http://www.fiercedeveloper.com), FierceFinance (http://www.fiercefinance.com), FierceFinanceIT (http://www.fiercefinanceit.com), FierceHealthCare (http://www.fiercehealthcare.com), FierceHealthFinance (http://www.fiercehealthfinance.com), FierceHealthIT (http://www.fiercehealthit.com), FierceIPTV (http://www.fierceiptv.com), FierceMobileContent (http://www.fiercemobilecontent.com), FierceMobileIT (http://www.fiercemovbileit.com), FierceOnlineVideo (http://www.fierceonlinevideo.com), FiercePharma (http://www.fiercepharma.com), FierceSarbox (http://www.fiercesarbox.com), FierceTelecom (http://www.fiercetelecom.com), FierceVaccines (http://www.fiercevaccines.com), FierceVoIP (http://www.fiercevoip.com), FierceWireless (http://www.fiercewireless.com), and FierceWireless: Europe (http://www.fiercewireless.com/europe).

Contacts:
Ashlea Kosikowski, Pure Communications
(910) 547-7093

Heather Cox, FierceMarkets, Inc.
(202) 628-8778 x13

Achaogen Data Show Rapid Rise in Rates of Resistance to Current Antibiotics; Illustrate Global Need for New, Well-Tolerated Agents to Address Varied Mechanisms of Resistance

- Data Presented at European Congress of Clinical Microbiology and Infectious Diseases -

SAN FRANCISCO, UNITED STATES and HELSINKI, FINLAND, May 16, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today the presentation of research on aminoglycoside (AG) resistance trends and comparative AG toxicities at the 19th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held May 16-19, 2009 in Helsinki, Finland.

In three separate sessions, Achaogen and its research collaborators, including the Jones Microbiology Institute Laboratories in Iowa and Paul M. Tulkens, M.D. of the Université catholique de Louvaine, Belgium, are highlighting study results that underscore the critical need for well-tolerated, next-generation AGs to combat multi-drug resistant Gram-negative pathogens and address a growing public health concern. AGs have been part of the clinical infectious disease armamentarium for roughly half a century; however, as the Achaogen and JMI Laboratories research shows, rates of bacterial resistance to existing AGs, including such widely used agents as gentamicin and amikacin, are far higher in all parts of the world than was expected, suggesting a need for a next-generation AGs that can treat these resistant pathogens.

“The data being presented at ECCMID demonstrate that global resistance to AGs is increasing more rapidly than previously thought, and shows that resistance mechanisms of various Gram-negative pathogens are limiting the utility of other currently marketed antibiotics across most, and possibly all known drug classes,” stated Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. “Bacteria are constantly evolving and becoming more resistant, and these findings reinforce the urgent need for new therapies to combat these varied mechanisms of resistance.”

Achaogen’s novel aminoglycoside agents—neoglycosides—have shown broad-spectrum efficacy in vitro and in vivo against a wide range of multi-drug resistant Gram-negative organisms (including E. coli, K. Pneumoniae, P. aeruginosa, and Enterobacter spp.), as well as multi-drug resistant Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus (VRSA). They also overcome known aminoglycoside resistance mechanisms. Achaogen’s most advanced neoglycoside, ACHN-490, is being studied in a Phase 1 trial and initial clinical data are expected later this year.

Overview of Findings
“Ten-year trend in aminoglycoside resistance from a worldwide collection of Gram-negative pathogens” (Saturday, May 16); Poster # 636
The study assessed resistance trends to aminoglycosides over a ten-year period, using a global sample of Gram-negative pathogens. This study determined the resistance rates of commonly prescribed AGs (gentamicin, tobramycin, amikacin) against over 20,000 bacterial strains from nine Gram-negative bacterial species gathered from medical centers around the world. In particular, resistance to AGs from E. coli, the most common Gram-negative pathogen isolated in the study, increased in all geographic regions. Notably, in regions outside of North America, more than 50% of Acinetobacter spp. and more than 20% of P. aeruginosa isolates collected during 1998-2007 were resistant to gentamicin. The highest rates of AG resistance were observed in the Latin America and Asia-Pacific regions. The study results underscore the global issue of bacterial resistance to available AGs, and the value of developing new therapies, such as Achaogen’s neoglycosides, to treat multi-drug resistant Gram-negative infections.

“Surveying aminoglycoside resistance mechanisms: a tool for the development of neoglycosides” (Saturday, May 16); Poster #643
Surveying AG resistance mechanisms among selected clinical isolates allows researchers to determine the spectrum of activity required of new compounds to overcome bacterial resistance to existing agents. In this study, multi-drug resistance was defined by resistance to three drug classes: aminoglycosides, fluoroquinolones and cephalosporins. The results demonstrate that while the overall prevalence of resistance to AGs is increasing, the distribution of AG-resistant mechanisms amongst AG-resistant isolates worldwide has remained stable during the past 20 years, suggesting that new agents that evade these mechanisms, such as neoglycosides, should remain useful for a long period of time against today’s AG-resistant bacteria.

In addition, a poster entitled “Quantitative comparison of aminoglycosides nephrotoxicity in rats for effective screening and evaluation of new derivatives, and dosing rationales that minimize toxicity,” Poster #1979, will be presented on Tuesday, May 19 at the ECCMID. This poster reviews data from a newly refined rat toxicity model that effectively quantifies the comparative nephrotoxicity of various aminoglycosides. This model allows for effective preclinical screening of Achaogen’s neoglycosides, and has informed the company’s selection of optimal dosing for clinical studies.

About ACHN-490
Achaogen’s novel aminoglycoside agents—neoglycosides—overcome known aminoglycoside resistance mechanisms. Leveraging modern chemistry and biology, as well as the extensive scientific and clinical knowledge gained from decades of aminoglycoside usage, Achaogen is poised to enhance the prominence and utility of this important class of antibacterials against 21st-century pathogens.

Achaogen’s lead neoglycoside, ACHN-490, has displayed efficacy in research and nonclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. The company initiated a Phase 1 clinical trial in early 2009 and data from this trial are expected in the second half of 2009.

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science, developing drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis.

South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

Contacts:
Ashlea Kosikowski, Pure Communications
(910) 547-7093

Achaogen Selected to Present at InsideVenture’s Debut Investor Conference

- March 25-26, Santa Barbara, California -

SAN FRANCISCO, CA, March 23, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific officer, will present at InsideVenture’s Debut Conference, March 25-26, 2009 in Santa Barbara, California. Achaogen has been selected from over 170 nominations to be one of 50 top private companies showcased to long-term investors through presentations and 1-on-1 meetings at the invitation only conference. InsideVenture’s Selection Boards includes Founders and Partners of leading venture firms including NEA, Venrock, DCM, Domain, Frazier, Clarus, Oak Investment, Aisling, and Versant. Over 130 investors are represented in the selected companies.

“We are honored to support Achaogen in their private funding efforts through our online platform and at our debut transactional conference in Santa Barbara,” said Mona DeFrawi, chief executive officer of InsideVenture. “InsideVenture was created as a powerful and cost-effective platform to support the companies that grow our economy by facilitating their late stage and pre-IPO financing needs. Structural changes in the capital markets over the past 10 years have blocked the real path to economic growth by challenging the financing of the companies delivering valuable new products, jobs and profits for the world economy. These top 50 companies have invested in innovation, and now InsideVenture is innovating the investment process to support their continued growth.”

“Achaogen is pleased to use InsideVenture’s new financing platform because it provides an efficient means to access and build relationships with a number of high quality private investors,” said Dr. Judice.

InsideVenture Investor Conference – March 25-26, Santa Barbara, California
Achaogen is one of 50 top late-stage private healthcare and technology companies seeking to raise $20-200+M or establish and develop relationships with new investors prior to an eventual IPO. The companies will present their businesses to qualified institutional buyers (QIBs), including mutual fund managers, crossover funds, late stage VC & PE funds and strategic corporate investors. Investors interested in attending the conference may apply for an InsideVenture trial membership; the conference is exclusive to members and by invitation only.  The theme of this year’s conference is “Investing in Innovation: Innovation in Investing”.  Investors should contact InsideVenture today to apply for membership and an invitation to the InsideVenture Investor Conference, March 25-26, 2009 in Santa Barbara, California.

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science to develop drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis. Achaogen is creating new medicines that anticipate the next wave of anti-bacterial infections, including agents for the underserved Gram-negative infectious disease market and methicillinresistant Staphylococcus aureus (MRSA). Achaogen’s most advanced compound, ACHN-490, one of the company’s next generation aminoglycosides known as neoglycosides, entered the clinic in January 2009, and the company has several other innovative small molecule antibacterial programs nearing clinical development. South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

About InsideVenture
InsideVenture is an industry sponsored financial marketing utility creating a direct private market platform for institutional and strategic investment in late-stage private companies. InsideVenture’s exclusive vetting and membership requirements connect the best late-stage
venture-backed companies with revered long-term institutional and strategic investors to facilitate late-stage transactions, IPO participation and aftermarket support. InsideVenture is supported by investment leaders and partners like T. Rowe Price, Wasatch Advisors, SVB
Financial Group, NYSE, Alexandria Equities, Intralinks Corporation, New Enterprise Associates, Domain Associates, DCM, Venrock Associates, Versant Ventures, Frazier Healthcare Ventures, Clarus Ventures, and Aisling Capital among others. InsideVenture is based in Menlo Park, California and on the web at www.insideventure.com.

InsideVenture Conference & Membership Contact:
Benjamin Levy, Vice President
650-926-0661
blevy@insideventure.com

InsideVenture Media Contact:
Matthew Stotts
TENOR
415.786.2231
matthew@tenorcom.com

Achaogen Contact:
Sondra Newman, Pure Communications
(617) 877-5687

Achaogen to Present at Cowen and Company 29th Annual Health Care Conference

SAN FRANCISCO, CA, March 10, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific officer, is scheduled to present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009 at 3:00 p.m. EDT at the Boston Marriott Copley Place in Boston, Mass.

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science to develop drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis. Achaogen is creating new medicines that anticipate the next wave of anti-bacterial infections, including agents for the underserved Gram-negative infectious disease market and methicillin-resistant Staphylococcus aureus (MRSA). Achaogen’s most advanced compound, ACHN-490, one of the company’s next generation aminoglycosides known as neoglycosides, entered the clinic in January 2009, and the company has several other innovative small molecule antibacterial programs nearing clinical development. South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

Contacts:
Sondra Newman, Pure Communications
(617) 877-5687

Achaogen Signs $26.6 Million Contract with NIAID for Development of New Therapy to Treat Resistant Strains of NIAID Category A and B Priority Pathogens

SAN FRANCISCO, CA, March 3, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that it has been awarded a contract worth up to $26.6 million over five years from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services. This award will fund the discovery and development of proprietary Achaogen compounds to combat biothreat strains of Gram-negative bacteria such as Yersinia pestis, the causative agent of bubonic plague, and Francisella tularensis, the causative agent of tularemia. This is Achaogen’s first award from NIAID, and brings the total non-dilutive capital secured by Achaogen from a variety of funding sources to over $100 million since its inception.

Achaogen’s neoglycosides, next-generation aminoglycosides, have shown broad-spectrum efficacy in vitro and in vivo against a wide range of multi-drug resistant Gram-negative organisms (including Pseudomonas, Acinetobacter and Enterobacteriaceae) as well as multi-drug resistant Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus strains). The NIAID funding will support Achaogen work to extend the spectrum and efficacy of its current leads, and to advance one neoglycoside through Phase 1 clinical trials.

“We are delighted that Achaogen has successfully competed for funding to advance our pipeline of novel therapies to multi-drug resistant antibacterial infections, including our expanded-spectrum neoglycosides portfolio,” said J. Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. “Achaogen shares NIAID’s commitment to addressing the global concerns of biothreat bacteria and antibiotic resistance. We are excited to be at the forefront of the development of potential solutions to these concerns.”

The project will be 100% federally funded in the amount of $26,660,078.

About Achaogen
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science to develop drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis. Achaogen is creating new medicines that anticipate the next wave of anti-bacterial infections, including agents for the underserved Gram-negative infectious disease market and methicillin-resistant Staphylococcus aureus (MRSA). Achaogen’s most advanced compound, ACHN-490, one of the company’s next generation aminoglycosides known as neoglycosides, entered the clinic in January 2009, and the company has several other innovative small molecule antibacterial programs nearing clinical development. South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

About NIAID
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research - at the National Institutes of Health (NIH), throughout the United States, and worldwide - to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

The NIH - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

Contacts:
Ashlea Kosikowski, Pure Communications
(910) 547-7093

Achaogen Initiates Phase 1 Trial of ACHN-490 for Treatment of Multi-Drug Resistant Gram-Negative Bacterial Infections

- Trial Initiation Marks Company’s First Neoglycoside to Enter Clinic -

SAN FRANCISCO, CA, February 3, 2009 – Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that it has initiated its first Phase 1 clinical trial. This trial is designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ACHN-490, the Company’s lead bactericidal agent, in at least 32 healthy volunteers. The trial – a randomized, double-blind, placebo-controlled, parallel group, dose-escalation study of intravenously administered ACHN-490 – is supported by the £4.1 million Seeding Drug Discovery award received from the Wellcome Trust, as announced by the Company last month.

Kevin Judice, Chief Executive Officer and Chief Scientific Officer of Achaogen, said, “We are very pleased that a promising neoglycoside compound discovered at Achaogen is being studied in our first clinical trial. We expect this initial clinical study of ACHN-490 to inform the dosing and trial design of our Phase 2 study in complicated urinary tract infection (cUTI), as well as additional future studies addressing complicated intra-abdominal infections, bloodstream infections and other serious, unmet medical needs in the hospital setting. We expect to complete this trial in 2009, and initiate a Phase 2 study in early 2010. The advancement of ACHN-490 and our entire portfolio – including our expanded spectrum neoglycosides in development – is indicative of our commitment to provide therapies to treat multi-drug resistant bacterial infections, particularly those caused by Gram-negative bacteria.”

ACHN-490 is the lead compound in Achaogen’s portfolio of proprietary neoglycosides, the Company’s unique, next-generation aminoglycoside antibiotics. It displays broad-spectrum activity against MDR Gram-negative bacteria that cause systemic infections, including highly resistant Enterobacteriaceae (e.g., E. coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA). In preclinical studies, ACHN-490 has demonstrated an acceptable safety profile and the potential for once-daily dosing. Achaogen will be exploring new dosing paradigms for its neoglycosides to maximize both efficacy and safety.
Aminoglycosides are a proven class of antibacterials in extensive clinical use, generating over $650 million in sales worldwide. There has not been a new member of this important class approved for decades, however, and the utility of existing aminoglycosides, like other classes of antibacterials, is declining rapidly due to the rapid spread of resistant bacterial strains – one of the most critical and worrisome issues facing healthcare today.

About Achaogen
Achaogen is an emerging biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science to develop drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis. Achaogen is creating new medicines that anticipate the next wave of anti-bacterial infections, including agents for the underserved Gram-negative infectious disease market and methicillin-resistant Staphylococcus aureus (MRSA), including its portfolio of next-generation aminoglycosides, the neoglycosides. South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the US Department of Defense, and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

Contacts:
Sondra Newman, Pure Communications
(617) 877-5687

Achaogen Receives ₤4.1 Million Award from the Wellcome Trust to Advance its Neoglycosides Portfolio

SAN FRANCISCO, CA, January 8, 2009 – Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that it has received a £4.1 million Seeding Drug Discovery award from the Wellcome Trust. This award will help support the investigational new drug (IND)-enabling studies and advancement into clinical trials of Achaogen’s portfolio of proprietary neoglycosides for the treatment of Gram-negative bacterial infections. Neoglycosides are Achaogen’s unique, next-generation aminoglycosides, in development to address the growing issue of multi-drug resistance to antibiotic agents.

“The escalation in resistance to even the most advanced antibiotics available today is one of our most concerning healthcare issues worldwide. Our support of Achaogen’s research recognizes the importance the Wellcome Trust places on this area of urgent need, and our commitment to help stop the spread of untreatable bacterial infections - especially Gram-negative infections - through hospitals, nursing homes and the wider community,” said Dr. Ted Bianco, Director of Technology Transfer at the Wellcome Trust.

The Wellcome Trust award supports ongoing preclinical studies of two Achaogen drug candidates: the Company’s lead compound ACHN-490, which has shown promising broad-spectrum activity against Gram-negative bacterial infections, including the highly resistant Enterobacteriaceae; plus a second set of leads with expanded-spectrum activity against multi-drug resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Both new chemical entities are being studied by Achaogen with the expectation of entering an initial product candidate into Phase 1 clinical development in 2009.

Aminoglycosides are a proven class of antibacterials that remain in extensive clinical use, generating over $650 million in sales worldwide. There has not been a new member of this important class approved for decades, however, and the utility of existing drugs is declining rapidly due to the expansion of resistant bacterial strains – one of the most critical and worrisome issues facing healthcare today.

Kevin Judice, Chief Executive Officer and Chief Scientific Officer of Achaogen, said, “We are very pleased to receive this funding award through the Seeding Drug Discovery Initiative of the Wellcome Trust. It is an honor that such a distinguished organization shares our vision and recognizes our potential to positively impact public health in the area of antibiotic resistance. We anticipate leveraging the wealth of experience and support made available to us through the Trust as we advance these compounds toward the clinic.”

About The Wellcome Trust
The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending over £600 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing.http://www.wellcome.ac.uk

Seeding Drug Discovery, established in 2005, is the Wellcome Trust’s five-year, £91 million initiative that aims to develop drug-like, small molecules that will be the springboard for further research and development by the biotechnology and pharmaceutical industry in areas of unmet medical need.

About Achaogen
Achaogen is an emerging biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science to develop drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis. Achaogen is creating new medicines that anticipate the next wave of anti-bacterial infections, including agents for the underserved Gram-negative infectious disease market and methicillin-resistant Staphylococcus aureus (MRSA), including its portfolio of next-generation aminoglycosides, the neoglycosides. South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the US Department of Defense, and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.

Contacts:
Sondra Newman, Pure Communications
(617) 877-5687

Achaogen Appoints Thomas B. King and Christopher T. Walsh to Board of Directors

SAN FRANCISCO, CA, December 17, 2008 – Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced the appointments of Thomas B. King, President and Chief Executive Officer of Alexza Pharmaceuticals (NASDAQ: ALXA), and Christopher T. Walsh, Ph.D., the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, to its Board of Directors.

“We are very pleased to welcome both Tom and Chris to our Board of Directors,” said Kevin Judice, Chief Executive Officer and Chief Scientific Officer of Achaogen. “Tom brings extensive biopharmaceutical company leadership and operational and advisory experience to Achaogen, and his strategic insights will be a significant asset to us as we move our innovative antibacterial products into clinical development. Dr. Walsh offers a rare and remarkable combination of both business and scientific expertise; he has been on the boards of several other successful enterprises, and is a world-renowned enzymologist with extensive knowledge of the evolution of antibiotic resistance and mechanisms of action. He is a valuable addition to our Board.”

Mr. King has served as President and Chief Executive Officer of Alexza Pharmaceuticals since 2003. Prior to joining Alexza, Mr. King served as President and Chief Executive Officer of Cognetix, Inc. His executive experience also includes seven years at the Anesta Corporation, where he held the positions of President and Chief Executive Officer. King previously held various marketing, business development and corporate development positions with Somatogen, Inc., Abbott Laboratories and Anaquest, a division of The BOC Group. He received an M.B.A. from the University of Kansas and a B.A. in chemistry from McPherson College.

“I am thrilled to join the Achaogen Board and look forward to working with the world-class team that Achaogen has assembled,” said King. “Within the next five years, Achaogen plans to become the global leader in the development of drugs to combat antibiotic-resistant pathogens. I look forward to being part of this critical mission addressing a growing area of medical concern.”

Dr. Walsh is currently the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, a position he has held since 1991. He has also served as President of the Dana-Farber Cancer Institute, Chairman of the Harvard Medical School Department of Biological Chemistry and Molecular Pharmacology, and Chairman of the MIT Chemistry Department. He has been a Trustee of the Whitehead Institute and the Helen Hay Whitney Foundation and a member of the scientific review board of the Howard Hughes Medical Institute. Dr. Walsh is currently on the Board of Directors for Magen Biosciences and Ironwood Pharmaceuticals (previously Microbia), and has previously been a Board member for a number of successful biotechnology companies, including Critical Therapeutics, ImmunoGen, Kosan Biosciences, Leukosite, TransForm Pharmaceuticals and Vicuron Pharmaceuticals. Dr. Walsh is a Scientific Advisory Board member for LS9 Inc. and HealthCare Ventures, and also served in this capacity for Sirtris Pharmaceuticals. He is a member of the National Academy of Sciences and the National Institute of Medicine of the National Academies. Dr. Walsh received a B.A. from Harvard University and a Ph.D. from The Rockefeller University, New York. Dr. Walsh was a postdoctoral fellow at Brandeis University.

Dr. Walsh commented, “The increase in resistance to even the most advanced antibiotics is one of the most concerning healthcare issues today. There exists a critical and unmet medical need for innovation and new mechanisms to overcome this global concern. Achaogen is poised to make a real difference, with its unique approach to the discovery and development of a broad pipeline of clinical candidates, including its portfolio of neoglycosides, next-generation aminoglycosides. I look forward to being involved with Achaogen as the company advances its novel compounds to combat multi-drug resistant bacteria, including Gram-negative infections.”

ABOUT ACHAOGEN
Achaogen is an emerging biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science to develop drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy is critical to address the global bacterial resistance crisis. Achaogen is creating new medicines that anticipate the next wave of anti-bacterial infections, including agents for the underserved Gram-negative infectious disease market and methicillin-resistant Staphylococcus aureus (MRSA). Achaogen’s most advanced compound, one of our next generation aminoglycosides known as neoglycosides, is entering the clinic in early 2009, and the company has several other innovative small molecule antibacterial programs nearing clinical development. South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from the NIH, the U.S. Department of Defense, and other sources. Venture capital investors include 5AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.